Queensland Bauxite to develop 'game-changing' cannabis pill

THE medical cannabis subsidiary of Queensland Bauxite (ASX: QBL) has signed a landmark deal with a Canadian company to develop a new cannabis pill, one which doctors will be able to recommend and officially prescribe to patients.

Queensland Bauxite's VitaCann division says the pill will be the first of its kind; a pharmaceutical-grade cannabis medicine which doctors will likely be more willing to prescribe than the drug's smoked alternative.

The company came out of a trading halt this morning to announce plans for the medication which it will develop in a joint venture with Toronto-based pharmaceutical company Canntab Therapeutics.

Following the announcement, QBL shares surged more than 71 per cent to trade at $0.089 at the time of writing (10:17am AEST).

There is currently no pharmaceutical-grade cannabis medicine yet available for doctors to prescribe anywhere in the world, however high-THC smoked marijuana is available in countries with health department exemptions including the United States, Canada and Israel.

VitaCann believes the new product could be a market disruptor. Read more

Paris Faint - Business News Australia - 9 Jan 2018

Comments

We welcome relevant, respectful comments.
Please read our Comment Policy before commenting.
We also welcome direct feedback via Contact Us.
You may also want to ask our librarians.

Be the first to write a comment